Lung Cancer

Skip to main content

Original Research, Checkpoint Inhibitors, Adverse Events, Lung Cancer

Impact of Hyperglycemia During Immune Checkpoint Inhibitor Treatment for Advanced Non–Small Cell Lung Cancer: A Retrospective, Single-Center Study

Allison L. Thurman, PharmD; Susan Storey, PhD, RN, ACONS, FCNS; David J. Reeves, PharmD, BCOP

Case Reports, Lung Cancer, Screening, Tyrosine Kinase Inhibitor

The Presence of De Novo EGFR T790M Mutation in a Tyrosine Kinase Inhibitor–Naïve Patient with Lung Adenocarcinoma: Case Report and Review of the Literature

Jessica Katiaj, PharmD; Rosemary Boshar, PharmD; Maryann R. Cooper, PharmD, BCOP; Gerald Gehr, MD

Case Reports, Lung Cancer, Tyrosine Kinase Inhibitor

Third-Line Tyrosine Kinase Inhibitor Therapy Results in 16-Year Remission in a Patient with Stage IV Non–Small-Cell Lung Cancer

Carrie L. Barnhart, PharmD, BCOP, and David F. Christianson, MD

Lung Cancer

2022 Midyear Review: Non–Small-Cell Lung Cancer

Meeting Highlights Online Only

AACR Highlights, Lung Cancer

First-Line Sotorasib Shows Long-Lasting Responses in Metastatic NSCLC with KRAS Mutation

FDA Updates, Lung Cancer, Checkpoint Inhibitors

Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC

Lung Cancer

Severe Adverse Events from Immune Checkpoint Inhibitor Therapy a Rare Concerning Side Effect

Lung Cancer

KRASᴳ¹²ᶜ Mutation–Positive Advanced NSCLC

Lung Cancer

CodeBreaK 100 Trial Results Demonstrate Sotorasib Conveys Clinical Benefit Across NSCLC Patient Subgroups

Lung Cancer

NSAID Use with Immune Checkpoint Inhibitors Associated with Longer Overall Survival in NSCLC

1
2
3
4

Page 1 of 12
Results 1 - 10 of 116